Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

NCT02834780 is registered in ClinicalTrials.gov with H3 Biomedicine Inc. as lead sponsor.

NCT NCT02834780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02834780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma
Lead sponsor
H3 Biomedicine Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 28, 2016
Completion date
February 23, 2022
Enrollment
128 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, hepatic cancer, hepatic carcinoma, hepatocellular carcinoma, liver cancer, liver neoplasms